Skip to main content
QCLS
NASDAQ Life Sciences

Q1 2026 Net Loss Narrows to $1.53M; Executive Chairman Secures New Compensation Package

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
7
Price
$4.6
Mkt Cap
$34.005M
52W Low
$2.5
52W High
$33.56
Market data snapshot near publication time

summarizeSummary

Q/C Technologies reported a narrowed net loss and improved EPS for Q1 2026, with management confirming a 12-month liquidity runway, while also disclosing a new compensation package for its Executive Chairman.


check_boxKey Events

  • Q1 2026 Financial Performance Improves

    The company reported a net loss attributable to common stockholders of $(1.53) million, a significant improvement from $(1.94) million in Q1 2025. Basic and diluted net loss per common share also improved to $(0.19) from $(0.36) year-over-year.

  • Liquidity Position and Cash Runway

    As of March 31, 2026, cash and cash equivalents totaled $1.13 million, with marketable securities at $11.85 million. Despite cash used in operating activities increasing to $3.29 million for the quarter, management believes current financial resources are sufficient to fund operations for the next twelve months.

  • Executive Chairman's New Employment Agreement

    Effective April 13, 2026, Executive Chairman Joshua Silverman entered a new three-year employment agreement, including an annual base salary of $120,000 and quarterly grants of fully vested restricted stock units (RSUs) valued at $60,000 per grant, plus an additional cash payment for estimated personal income and employment taxes on the RSUs.

  • Strategic Business Pivot Continues

    The company reiterated its ongoing strategic shift from pharmaceuticals to energy-efficient blockchain and quantum-class laser-based computing, leveraging an exclusive global licensing agreement with LightSolver Ltd. The legacy pharmaceutical assets are being evaluated for potential divestiture.


auto_awesomeAnalysis

Q/C Technologies reported a narrower net loss for Q1 2026, improving to $(1.53) million from $(1.94) million year-over-year, and management affirmed sufficient liquidity for the next 12 months. This is critical for a micro-cap company that remains pre-revenue and is undergoing a strategic pivot. Additionally, the Executive Chairman, Joshua Silverman, entered a new employment agreement with a notable compensation package, including significant RSU grants and associated tax payments, which provides transparency into executive incentives.

At the time of this filing, QCLS was trading at $4.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34M. The 52-week trading range was $2.50 to $33.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed QCLS - Latest Insights

QCLS
May 15, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
QCLS
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
QCLS
Apr 29, 2026, 5:19 PM EDT
Filing Type: 10-K/A
Importance Score:
9
QCLS
Apr 15, 2026, 5:20 PM EDT
Filing Type: 10-K
Importance Score:
9
QCLS
Mar 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
QCLS
Feb 11, 2026, 5:17 PM EST
Filing Type: S-3
Importance Score:
8
QCLS
Jan 23, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
8